belzutifan
Sponsor Merck & CO INC. · listed as MRK
belzutifan is a drug asset sponsored by Merck & CO INC., listed as MRK. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 28, 2026 (day precision, medium confidence), tied to trial NCT05239728. That trial is in Phase 3 and currently active not recruiting, studying Carcinoma, Renal Cell. It appears across 8 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for belzutifan in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT04195750 | Phase 3 | Active, not recruiting | 2024-04-15 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| NCT04586231 | Phase 3 | Active, not recruiting | 2026-02-02 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| NCT04736706 | Phase 3 | Active, not recruiting | 2026-02-04 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| NCT05899049 | Phase 3 | Active, not recruiting | 2026-02-04 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| NCT05239728 catalyst | Phase 3 | Active, not recruiting | 2026-10-28 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| NCT07489495 | Phase 3 | Recruiting | 2030-11-27 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| NCT07227402 | Phase 3 | Recruiting | 2032-02-27 | Experimental | Merck Sharp & Dohme LLC | Renal Cell Carcinoma |
| NCT07405164 | Phase 3 | Recruiting | 2034-04-22 | Experimental | Merck Sharp & Dohme LLC | Von Hippel-Lindau Disease; Malignant Neoplasms |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More MRK catalysts